Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 3/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6013056 | 0.70 | ESR1 (0.41) | AOC3ESR1ESR2NR1H2NR1H3 | |
| SCHEMBL2102111 | 0.70 | KCNN4 (0.36) | AOC3ESR1ESR2KCNN4NR1H2 | |
| SCHEMBL2271603 | 0.70 | KCNN4 (0.36) | AOC3ESR1ESR2KCNN4NR1H2 | |
| SCHEMBL564255 | 0.69 | NR1H2 (0.39) | AOC3ESR1ESR2NR1H2NR1H3 | |
| SCHEMBL272814 | 0.69 | NR1H2 (0.39) | AOC3ESR1ESR2NR1H2NR1H3 | |
| SCHEMBL152027 | 0.69 | NR1H2 (0.39) | AOC3ESR1ESR2NR1H2NR1H3 | |
| SCHEMBL3526796 | 0.67 | ESR1 (0.37) | AOC3ESR1ESR2KCNN4NR1H2 | |
| SCHEMBL3888384 | 0.67 | ESR1 (0.37) | AOC3ESR1ESR2KCNN4NR1H2 | |
| SCHEMBL29749402 | 0.67 | ESR1 (0.37) | AOC3ESR1ESR2KCNN4NR1H2 | |
| SCHEMBL20328588 | 0.67 | ESR1 (0.37) | AOC3ESR1ESR2KCNN4NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266954-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | Draximage, Inc. (CA) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266953-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | Draximage, Inc. (CA) | 2010-12-29 | — | — | EP | disclosed |
| US-7238339-B2 | Bifunctional chelating compounds containing hydroxamic acid residues | DRAXIS SPECIALTY PHARMACEUTICALS INC. (CA) | 2007-07-03 | — | — | US | disclosed |
| US-20040086460-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | JUBILANT DRAXIMAGE INC. (CA) | 2004-05-06 | — | — | US | disclosed |
| EP-1351926-A2 | NOVEL BIFUNCTIONAL CHELATING COMPOUNDS CONTAINING HYDROXAMIC ACID RESIDUES | Draximage, Inc. (CA) | 2003-10-15 | — | — | EP | disclosed |
| US-6623721-B2 | Conjugates can be complexed to a radioisotope metallic element and used for diagnosing or treating receptor-positive tumors | DRAXIMAGE, INC. (CA) | 2003-09-23 | — | — | US | disclosed |
| WO-2002068379-A2 | NOVEL BIFUNCTIONAL CHELATING COMPOUNDS CONTAINING HYDROXAMIC ACID RESIDUES | DRAXIMAGE, INC. (CA) | 2002-09-06 | — | — | WO | disclosed |
| US-20020076377-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | JUBILANT DRAXIMAGE INC. (CA) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020076377-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | EPRS1, HAMP, PHPT1 | AOC3 2123/4885ESR1 3740/4885ESR2 3143/4885 |
| US-20040086460-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | EPRS1, HAMP, PHPT1 | AOC3 2123/4885ESR1 3740/4885ESR2 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.